RXRX241220P6500
- 0.04
- -0.15-78.95%
Recursion Pharmaceuticals Newsroom
Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX)
Trending Industry Today: SoundHound AI Leads Gains In NVIDIA Portfolio Stocks
Trending Industry Today: Applied Digital Leads Gains In NVIDIA Portfolio Stocks
Recursion Pharmaceuticals' (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials
Hold Rating for Recursion Pharmaceuticals Amid Early Efficacy Signals and Financial Concerns
10 Health Care Stocks Whale Activity In Today's Session
Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11
Express News | Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings
TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
TD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $12
Cautious Optimism for Recursion Pharmaceuticals Amid Promising Safety Profile and Upcoming Milestones
10 Health Care Stocks With Whale Alerts In Today's Session
What's Going On With Recursion Pharmaceuticals Stock?
Recursion Pharmaceuticals Says Potential Advanced Solid Tumor Treatment Well Tolerated
Recursion Reports Promising Phase 1/2 Data for REC-617, a CDK7 Inhibitor, in Advanced Solid Tumors
Express News | Recursion Pharmaceuticals Inc: Plans to Continue Monotherapy Dose Escalation and Initiate Combination Studies in 1H 2025
Express News | Recursion Pharmaceuticals Inc: REC-617 Well-Tolerated With No Discontinuations Due to Adverse Events